Related Experiment Video
Updated: Sep 19, 2025
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Omega-3 fatty acids: multi-target mechanisms and therapeutic applications in neurodevelopmental disorders and
Miao Li1, Zhiqiang Li1, Yuying Fan1
1Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Insights
Omega-3 fatty acids, like DHA and EPA, show promise in managing neurodevelopmental disorders (NDDs) and epilepsy by protecting brain cells. Improving their bioavailability through innovative nutrition is key for better treatment outcomes.
Area of Science:
- Neuroscience
- Nutritional Science
- Pediatric Neurology
Background:
- Neurodevelopmental disorders (NDDs) such as ADHD, ASD, and Tourette's syndrome impact child development.
- Epilepsy shares pathological pathways with NDDs, including neuroinflammation and oxidative stress.
- Omega-3 fatty acids (DHA, EPA) possess neuroprotective and neuromodulatory properties relevant to these conditions.
Purpose of the Study:
- To review the multifaceted roles of omega-3 fatty acids in NDDs and epilepsy.
- To highlight omega-3s as a potential core component in integrated treatment strategies.
- To discuss limitations in bioavailability and suggest future directions for optimizing intake.
Main Methods:
- Literature review summarizing existing research on omega-3 fatty acids in NDDs and epilepsy.
- Analysis of omega-3 mechanisms, including Nrf2/ARE pathway activation, oxidative stress reduction, and gut-brain axis modulation.
- Examination of bioavailability challenges and potential solutions, such as functional foods and combination therapies.
Main Results:
- Omega-3s demonstrate neuroprotective effects via multiple pathways, including antioxidant and anti-inflammatory actions.
- Activation of the Nrf2/ARE pathway and regulation of the gut-brain axis are key mechanisms.
- Limited bioavailability necessitates strategies to enhance absorption and efficacy.
Conclusions:
- Omega-3 fatty acids offer a safe and effective approach for NDDs and epilepsy symptom management.
- Integrated treatment strategies combining omega-3s with other therapies or functional foods are promising.
- Future research should focus on precision nutrition and advanced functional food development to maximize therapeutic benefits.
Abstract:
Neurodevelopmental disorders (NDDs), including attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and Tourette's syndrome (TS), impair brain development and function, primarily affecting cognition, behavior, and social skills in children. Epilepsy, characterized by recurrent seizures due to neuronal hyperexcitability, shares pathological mechanisms with NDDs, such as neuroinflammation, synaptic dysfunction, and oxidative stress. Omega-3 fatty acids-primarily docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)-exert neuroprotective and neuromodulatory effects in these conditions through multifaceted mechanisms. Omega-3 fatty acids play a role in activating the Nrf2/ARE pathway, protecting neurons from oxidative damage, regulating the gut-brain axis, and regulating the balance of microflora. Although Omega-3 fatty acids have a natural safety advantage in improving NDDs and epilepsy symptoms, the bioavailability is limited by the source, formulation form, and dietary environment. Current studies point out that monotherapy has a limited effect and requires a combination of vitamin D, probiotics, or drugs, as well as the development of innovative functional foods to improve intake efficiency. This review summarizes the multi-pathway roles of Omega-3 fatty acids in NDDs and epilepsy, emphasizing the potential as a core component of integrated treatment strategies. Future studies should prioritize precision nutrition approaches and functional food development to optimize patient outcomes in neuropsychiatric care.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:31Neurotransmitters
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...